EcoDrugPlus

5-Hydroxytryptamine Receptor 2c

Ensembl ID : ENSMLUG00000000264
Gene Symbol: HTR2C
2 Cross references
223 Possible Orthologues:

5-Hydroxytryptamine Receptor 3a

Ensembl ID : ENSMLUG00000002642
Gene Symbol: LOC102437885
3 Cross references
204 Possible Orthologues:

5-Hydroxytryptamine Receptor 3a

Ensembl ID : ENSMLUG00000008598
Gene Symbol: HTR3A
3 Cross references
204 Possible Orthologues:

5-Hydroxytryptamine Receptor 3b

Ensembl ID : ENSMLUG00000008575
Gene Symbol: HTR3B
4 Cross references
174 Possible Orthologues:

5-Hydroxytryptamine Receptor 4

Ensembl ID : ENSMLUG00000003382
Gene Symbol: HTR4
2 Cross references
200 Possible Orthologues:

5-Hydroxytryptamine Receptor 5a

Ensembl ID : ENSMLUG00000014427
Gene Symbol: HTR5A
2 Cross references
210 Possible Orthologues:

5-Hydroxytryptamine Receptor 7

Ensembl ID : ENSMLUG00000017165
Gene Symbol: HTR7
2 Cross references
219 Possible Orthologues:

60s Acidic Ribosomal Protein P1

Ensembl ID : ENSMLUG00000010542
Gene Symbol: LOC102426061
3 Cross references
159 Possible Orthologues:

60s Ribosomal Protein L36a-Like

Ensembl ID : ENSMLUG00000013891
Gene Symbol: LOC102422971
3 Cross references
76 Possible Orthologues:

A-Raf Proto-Oncogene, Serine/threonine Kinase

Ensembl ID : ENSMLUG00000014746
Gene Symbol: ARAF
2 Cross references
190 Possible Orthologues:

Abl Proto-Oncogene 1, Non-Receptor Tyrosine Kinase

Ensembl ID : ENSMLUG00000008799
Gene Symbol: ABL1
2 Cross references
202 Possible Orthologues:

Adam Metallopeptidase Domain 17

Ensembl ID : ENSMLUG00000010676
Gene Symbol: ADAM17
2 Cross references
282 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).